CANMAT depression guidelines: Recommendations for first-line (level 1 evidence) antidepressants. Level 1 evidence includes meta-analysis with narrow confidence intervals or 2 or more randomized placebo-controlled trials with adequate sample size available to support use in depression treatment.
| CLASS | AGENT | DAILY DOSE |
|---|---|---|
| SSRI | Citalopram | 20-40 mg |
| Escitalopram | 10-20 mg | |
| Fluoxetine | 20-60 mg | |
| Fluvoxamine | 100-300 mg | |
| Paroxetine | IR: 20-50 mg CR: 25-62.5 mg | |
| Sertraline | 50-200 mg | |
| SNRI | Desvenlafaxine | 50-100 mg |
| Duloxetine | 60 mg | |
| Venlafaxine | 75-225 mg | |
| NDRI | Bupropion | 150-300 mg |
| Other | Mirtazapine | 15-45 mg |
| Vortioxetine | 10-20 mg | |
| Not available in Canada | Agomelatine | 25-50 mg |
| Mianserin | 60-120 mg | |
| Milnacipran | 100 mg |
CANMAT—Canadian Network for Mood and Anxiety Treatments, CR—controlled release, IR—immediate release, NDRI—norepinephrine-dopamine reuptake inhibitor, SNRI—serotonin-norepinephrine reuptake inhibitor, SSRI—selective serotonin reuptake inhibitor.
Reprinted with permission from the Canadian Psychiatric Association,19 copyright ©2016; permission conveyed through Copyright Clearance Center, Inc.